// App-Quantinova.ai

12923 : Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes

Researchers

Presenter

  • David D Berg

Principal Investigators

  • Stephen D Wiviott

  • Benjamin M Scirica

  • Erica Goodrich

  • Deepak L Bhatt

  • Lawrence A Leiter

  • Darren K McGuire

  • JOHN WILDING

  • Per Johanson

  • Anna Maria Langkilde

  • Eugene Braunwald

  • Marc S Sabatine

  • David A Morrow

Medical Centers

  • TIMI Study Group, Brigham and Women's Hosp, Boston, MA

  • Brigham & Women's Hospital, Boston, MA

  • Brigham & Women's Hospital, Boston, MA

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

  • ST MICHAEL S HOSPITAL, Toronto, Canada

  • UT SOUTHWESTERN MEDICAL CENTER, Plano, TX

  • Univ of Liverpool, LIVERPOOL

  • AstraZeneca, Molndal, Sweden

  • ASTRAZENECA, M Lndal, Sweden

  • Weston, MA

  • TIMI Study Group, Boston, MA

Locations

  • United States

  • Canada

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Congestive heart failure

  • Diabetes

  • Type 2 diabetes mellitus

Biomarkers

  • B-type natriuretic peptide

  • N-terminal pro b-type natriuretic peptide

  • High-sensitivity cardiac troponin T

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved